TARGET INTRAOCULAR
PRESSURE (IOP)
LT COL A.K.M. RASHED-UL-HASAN
F.C.P.S, D.O
Long term fellow trainee (Glaucoma)
Introduction
 Glaucoma
 progressive optic neuropathy as a results of RGCs
loss
 VFL
 IOP- important risk factor & only factor that can
be modified at present time
 Reducing IOP is currently the only clinically proven
way to slow down the progression of glaucoma
 Fundamental goal-
 Slowing the rate of RGCs loss to age dependent rate
 Reduce the rate of progression of Glaucomatous
damage
Target IOP
 A “target” pressure should be set as a goal of long
term therapy.
 It should be chosen on an individual basis, weighing
potential benefits and risks of treatment for each
patient.
 Definition: “upper limit of IOP that prevents
further glaucomatous damage”
 Also called the “Ideal pressure”, “safe level of IOP”
Evidence from Clinical Studies
 Ocular Hypertension Treatment Study (OHTS)
 ≥20% reduction of IOP from initial value, leads to a
lower rate of glaucoma progression in OHT patients.
 Collaborative Initial Glaucoma Treatment Study (CIGTS)
 To determine newly dx pts with POAG are better treated
initially with medication Vs filtering Sx.
 Both lowered IOP; Sx >medication
 Glaucoma progress will be minimal if pts are treated
aggressively to achieve low target pressure.
 Early Manifest Glaucoma Trial (EMGT)
 Compare the effect of immediate t/t to lower IOP Vs
no t/t on progression of newly detected POAG.
 For every 1 mm drop in IOP
, a 10% reduction in risk
of glaucomatous progression was observed.
 Early t/t reduces & delays glaucoma progression
 Advanced Glaucoma Intervention Study (AGIS)
 Trabeculectomy Vs laser trabeculoplasty in pts
with IOP uncontrolled by medication
 Target IOP was set at <18 mmHg
 Follow-up pts with lower IOP were free from
visual field impairment.
 Collaborative Normal Tension Glaucoma Study (CNTGS)
 Effect of IOP decrease in patients with NTG or
low tension glaucoma
 ≥30% IOP reduction from base line, decrease
delayed the progression of glaucomatous lesions
by 3 years
Establishing a target IOP
Why?
When?
To maintain functional vision throughout the
patients lifetime with a minimal effect on
quality of life
On initial visit & review periodically
How? Individualized
Assessment of target IOP
 Based on an individual glaucoma risk assessment
1. Estimation of amount of glaucoma damage (opticdisc
and visual field assessment).
 If advanced optic nerve damage at the time of
diagnosis, set lower target IOP & vice versa
2.Appreciation of the damaging IOP or “maximum” IOP at
which damage has occurred.
 lower IOP at initial presentation, set lower target IOP &
vice versa
3. Life expectancy of pts.
 High expectancy, set lower the target IOP & vise versa.
4. Identification of the other risk factors for progression
(presence of a severe damage in other eye, family
history of blindness from glaucoma, high myopia,
ethnicity, vascular risk factors)
5. Assessment of the rate of progression of glaucoma
damage, i.e severity of damage that has already
occurred versus time.
6. Centre corneal thickness
Factors Set High target IOP Set Low target IOP
Initial presentation Higher IOP Lower IOP
Life expectance Shorter Longer
ONH damage Early Advanced
1. Percentage drop in IOP
2. Absolute reduction
HOW TO CALCULATE A TARGET
PRESSURE
HOW TO CALCULATE A TARGET
PRESSURE
1. IOP < 21 mm Hg
2. Lower IOP by 20%-30% from base line
3. Lower IOP by 1/3 of base line
1. Zeyen’s simpler version
Target IOP = Max IOP – Max IOP% - Z
Z = Optic nerve damage severity factor
2. CIGTS Formula
Target IOP = [1-{ ref IOP + VF score } / 100 ] x [ ref IOP ]
3. Modified Jampel Target IOP
, 1999
FORMULA TO CALCULATE
TARGET PRESSURE
Modified Jampel Target IOP
, 1999
 Ex. IP- 30 , Z- 2
 TP= 30 (1-30/100)-2 ± 2 = 19±2 mm Hg
1. MILD GLAUCOMA
Characteristics Optic Nerve abnormality
No Visual Field Abnormality
2. MODERATE GLAUCOMA
Characteristics Optic Nerve abnormality
Visual Field Abnormality
in one hemi-field but not within 5° of fixation
3. SEVERE GLAUCOMA
Characteristics Optic Nerve abnormality
Visual Field Abnormality
in both hemi-field and within 5° of fixation
GRADING SYSTEM BY AAO
AAO GUIDELINES: TARGET IOP
Clinical conditions Target IOP
1. Mild glaucoma Reduction of 20% from baseline /
IOP 17-18 mm of Hg
2. Moderate glaucoma Reduction of 30% from baseline/
IOP 14-16 mm of Hg
3. Advanced Glaucoma Reduction of 35-40% from
baseline / IOP 10-12 mm of Hg
4. Ocular hypertension Reduction of 20% from baseline
6. Normal pressure glaucoma or NTG Reduction of 30% from baseline
Target IOP Lt Col Rashed
Recommended target IOPs in the
Guidelines of the European Glaucoma
Society (2003)
POAG Target IOP
Early Glaucoma <18 mm Hg
Mod Glaucoma <15 mm Hg
Adv Glaucoma <12 mm Hg
Terminal Glaucoma <10 mm Hg
NTG Target IOP
Early Glaucoma <15 mm Hg
Mod Glaucoma <12 mm Hg
Adv
Glaucoma
<10 mm Hg
HOW TO USE A TARGET
PRESSURE
 Draw an IOP curve for each glaucomatous patient
and to highlight the target pressure on the curve.
 Target pressures should be reevaluated periodically.
 10 yrs later patient may develope any new systemic
or ocular conditions that might affect the
risk/benefit ratio of therapy.
HOW TO USE A TARGET PRESSURE
cont..
 Target pressure needs to be lowered if
glaucomatous damage is progressing despite IOP’s
below the initially set target.
 Conversely, the target IOP range may have to be
increased if achieving the target IOP causes
adverse ocular or systemic side effects.
Listen to Expert
“ You’re not going to have one target pressure that’s
appropriate for every patient. It is a dynamic process
and you always have to be alert and open to
modification.”
L. Jay Katz,
Professor of Ophthalmology
Jefferson Medical College
Listen to Expert
“Patients should be followed closely over time and their
target pressures should be adjusted, depending upon
how the patient is doing. If the patient progresses, the
target pressure should be lowered. If the patient does
very well, the target might be raised.”
Stevens Simmons,
Associate Clinical Professor,
Albany Medical College
Target Intraocular Pressure
Calculator
Key Points
 IOP is a significant, modifiable risk factor in Glaucoma
 Lowering IOP to a target level is helpful across the spectrum of
ds states & IOP levels:
 Advanced glaucoma
 Normal tension glaucoma
 Newly diagnosed glaucoma
 Target IOP range must be:
 Individualized
 Re-evaluated periodically
Target IOP Lt Col Rashed

More Related Content

PPTX
Neovascular glaucoma (NVG)
PPTX
Iol power calculation in pediatric patients
PPTX
Anterior segment OCT & UBM
PPT
Pentacam
PDF
Evaluation of preperimetric glaucoma
PPTX
Iridocorneal endothelial syndrome
PPT
Target IOP
PPTX
Vitreous substitutes
Neovascular glaucoma (NVG)
Iol power calculation in pediatric patients
Anterior segment OCT & UBM
Pentacam
Evaluation of preperimetric glaucoma
Iridocorneal endothelial syndrome
Target IOP
Vitreous substitutes

What's hot (20)

PPTX
Macular disorders best disease
PPT
Orbscan &amp; topo
PPTX
IOL POWER CALCULATION IN CHILDREN-Dr.Preetiilal.pptx
PPTX
Ice syndrome
PDF
Esotropia
PPTX
IMAGING TECHNIQUES IN GLAUCOMA
PPTX
Optic disc evaluation
PPTX
Oct in glaucoma
PPTX
Specular microscopy
PPT
OPTIC DISC PIT Pathogenesis and Management
PPTX
Amniotic membrane in ophthalmology
PPTX
Glaucoma drainage devices
PPT
10-subluxated-lens.ppt
PPTX
FFA and ICG
PPTX
Multifocal iols
PPTX
Optical coherence tomography in glaucoma - Dr Shylesh Dabke
PPTX
Diabetic macular edema
PDF
Intrastromal Corneal Ring Segment (ICRSs)
PPTX
Neuroprotection in glaucoma - A brief review
PPTX
Normal tension glaucoma
Macular disorders best disease
Orbscan &amp; topo
IOL POWER CALCULATION IN CHILDREN-Dr.Preetiilal.pptx
Ice syndrome
Esotropia
IMAGING TECHNIQUES IN GLAUCOMA
Optic disc evaluation
Oct in glaucoma
Specular microscopy
OPTIC DISC PIT Pathogenesis and Management
Amniotic membrane in ophthalmology
Glaucoma drainage devices
10-subluxated-lens.ppt
FFA and ICG
Multifocal iols
Optical coherence tomography in glaucoma - Dr Shylesh Dabke
Diabetic macular edema
Intrastromal Corneal Ring Segment (ICRSs)
Neuroprotection in glaucoma - A brief review
Normal tension glaucoma
Ad

Similar to Target IOP Lt Col Rashed (20)

PPT
Target IOP is intraocular pressure at which optic nerve damage is minimal or ...
PPTX
CCT and TARGET PRESSURE in Glaucoma Management - Pfizer Symposium.pptx
PPTX
classification and management of glaucoma.pptx
PPTX
Medical management of glaucoma
PPTX
Medical management of glaucoma
PPTX
Important trials in Glaucoma
PDF
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
PPTX
Major review of important trial in glaucoma
PPTX
RecentPlaces.lnk.pptx ppt on glaucoma medications
PPTX
Glaucoma ppt
PDF
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
PPTX
Glaucoma and dgharia of bgf vfcvf vf .pptx
PPTX
Primary Open Angle Glaucoma
PPT
PPTX
GLAUCOMA MEDICATION.pptx
PPTX
Combination Therapy for Glaucoma Management (1).pptx
PPTX
Narrow angles
PDF
Glaucoma
PDF
Iop compliance and fluctuations
PPT
Final fp 0007 AIOS 2007, Hydrabad
Target IOP is intraocular pressure at which optic nerve damage is minimal or ...
CCT and TARGET PRESSURE in Glaucoma Management - Pfizer Symposium.pptx
classification and management of glaucoma.pptx
Medical management of glaucoma
Medical management of glaucoma
Important trials in Glaucoma
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Major review of important trial in glaucoma
RecentPlaces.lnk.pptx ppt on glaucoma medications
Glaucoma ppt
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
Glaucoma and dgharia of bgf vfcvf vf .pptx
Primary Open Angle Glaucoma
GLAUCOMA MEDICATION.pptx
Combination Therapy for Glaucoma Management (1).pptx
Narrow angles
Glaucoma
Iop compliance and fluctuations
Final fp 0007 AIOS 2007, Hydrabad
Ad

More from Rashed-Ul-Hasan Rasu (9)

PPTX
Hvfa humphrey visual field
PPTX
OCT in glaucoma ppt;1
PPTX
Complication of catarct surgery
PPTX
Perimetry & Humprey visual field assay (HVFA)
PPTX
Corneal ulcer short case
PPTX
Idiopathic intracranial hypertension
PPTX
Long case marfan syndrome
PPT
Ocular surface squamous neoplasia
PPTX
Evaluation of a glaucoma patient
Hvfa humphrey visual field
OCT in glaucoma ppt;1
Complication of catarct surgery
Perimetry & Humprey visual field assay (HVFA)
Corneal ulcer short case
Idiopathic intracranial hypertension
Long case marfan syndrome
Ocular surface squamous neoplasia
Evaluation of a glaucoma patient

Recently uploaded (20)

PPTX
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
PPTX
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
PDF
The Digestive System Science Educational Presentation in Dark Orange, Blue, a...
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PDF
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
PPTX
Effects of lipid metabolism 22 asfelagi.pptx
PPTX
Electrolyte Disturbance in Paediatric - Nitthi.pptx
PPTX
Wheat allergies and Disease in gastroenterology
PPTX
09. Diabetes in Pregnancy/ gestational.pptx
PDF
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PPT
Infections Member of Royal College of Physicians.ppt
PPTX
Approach to chest pain, SOB, palpitation and prolonged fever
PPTX
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
PPTX
preoerative assessment in anesthesia and critical care medicine
PDF
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
PDF
AGE(Acute Gastroenteritis)pdf. Specific.
PPTX
y4d nutrition and diet in pregnancy and postpartum
PPTX
Post Op complications in general surgery
PPTX
Reading between the Rings: Imaging in Brain Infections
PDF
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
The Digestive System Science Educational Presentation in Dark Orange, Blue, a...
nephrology MRCP - Member of Royal College of Physicians ppt
SEMEN PREPARATION TECHNIGUES FOR INTRAUTERINE INSEMINATION.pdf
Effects of lipid metabolism 22 asfelagi.pptx
Electrolyte Disturbance in Paediatric - Nitthi.pptx
Wheat allergies and Disease in gastroenterology
09. Diabetes in Pregnancy/ gestational.pptx
focused on the development and application of glycoHILIC, pepHILIC, and comm...
Infections Member of Royal College of Physicians.ppt
Approach to chest pain, SOB, palpitation and prolonged fever
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
preoerative assessment in anesthesia and critical care medicine
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
AGE(Acute Gastroenteritis)pdf. Specific.
y4d nutrition and diet in pregnancy and postpartum
Post Op complications in general surgery
Reading between the Rings: Imaging in Brain Infections
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf

Target IOP Lt Col Rashed

  • 1. TARGET INTRAOCULAR PRESSURE (IOP) LT COL A.K.M. RASHED-UL-HASAN F.C.P.S, D.O Long term fellow trainee (Glaucoma)
  • 2. Introduction  Glaucoma  progressive optic neuropathy as a results of RGCs loss  VFL  IOP- important risk factor & only factor that can be modified at present time  Reducing IOP is currently the only clinically proven way to slow down the progression of glaucoma
  • 3.  Fundamental goal-  Slowing the rate of RGCs loss to age dependent rate  Reduce the rate of progression of Glaucomatous damage
  • 4. Target IOP  A “target” pressure should be set as a goal of long term therapy.  It should be chosen on an individual basis, weighing potential benefits and risks of treatment for each patient.  Definition: “upper limit of IOP that prevents further glaucomatous damage”  Also called the “Ideal pressure”, “safe level of IOP”
  • 5. Evidence from Clinical Studies  Ocular Hypertension Treatment Study (OHTS)  ≥20% reduction of IOP from initial value, leads to a lower rate of glaucoma progression in OHT patients.  Collaborative Initial Glaucoma Treatment Study (CIGTS)  To determine newly dx pts with POAG are better treated initially with medication Vs filtering Sx.  Both lowered IOP; Sx >medication  Glaucoma progress will be minimal if pts are treated aggressively to achieve low target pressure.
  • 6.  Early Manifest Glaucoma Trial (EMGT)  Compare the effect of immediate t/t to lower IOP Vs no t/t on progression of newly detected POAG.  For every 1 mm drop in IOP , a 10% reduction in risk of glaucomatous progression was observed.  Early t/t reduces & delays glaucoma progression
  • 7.  Advanced Glaucoma Intervention Study (AGIS)  Trabeculectomy Vs laser trabeculoplasty in pts with IOP uncontrolled by medication  Target IOP was set at <18 mmHg  Follow-up pts with lower IOP were free from visual field impairment.
  • 8.  Collaborative Normal Tension Glaucoma Study (CNTGS)  Effect of IOP decrease in patients with NTG or low tension glaucoma  ≥30% IOP reduction from base line, decrease delayed the progression of glaucomatous lesions by 3 years
  • 9. Establishing a target IOP Why? When? To maintain functional vision throughout the patients lifetime with a minimal effect on quality of life On initial visit & review periodically How? Individualized
  • 10. Assessment of target IOP  Based on an individual glaucoma risk assessment 1. Estimation of amount of glaucoma damage (opticdisc and visual field assessment).  If advanced optic nerve damage at the time of diagnosis, set lower target IOP & vice versa 2.Appreciation of the damaging IOP or “maximum” IOP at which damage has occurred.  lower IOP at initial presentation, set lower target IOP & vice versa
  • 11. 3. Life expectancy of pts.  High expectancy, set lower the target IOP & vise versa. 4. Identification of the other risk factors for progression (presence of a severe damage in other eye, family history of blindness from glaucoma, high myopia, ethnicity, vascular risk factors) 5. Assessment of the rate of progression of glaucoma damage, i.e severity of damage that has already occurred versus time. 6. Centre corneal thickness
  • 12. Factors Set High target IOP Set Low target IOP Initial presentation Higher IOP Lower IOP Life expectance Shorter Longer ONH damage Early Advanced
  • 13. 1. Percentage drop in IOP 2. Absolute reduction HOW TO CALCULATE A TARGET PRESSURE
  • 14. HOW TO CALCULATE A TARGET PRESSURE 1. IOP < 21 mm Hg 2. Lower IOP by 20%-30% from base line 3. Lower IOP by 1/3 of base line
  • 15. 1. Zeyen’s simpler version Target IOP = Max IOP – Max IOP% - Z Z = Optic nerve damage severity factor 2. CIGTS Formula Target IOP = [1-{ ref IOP + VF score } / 100 ] x [ ref IOP ] 3. Modified Jampel Target IOP , 1999 FORMULA TO CALCULATE TARGET PRESSURE
  • 16. Modified Jampel Target IOP , 1999  Ex. IP- 30 , Z- 2  TP= 30 (1-30/100)-2 ± 2 = 19±2 mm Hg
  • 17. 1. MILD GLAUCOMA Characteristics Optic Nerve abnormality No Visual Field Abnormality 2. MODERATE GLAUCOMA Characteristics Optic Nerve abnormality Visual Field Abnormality in one hemi-field but not within 5° of fixation 3. SEVERE GLAUCOMA Characteristics Optic Nerve abnormality Visual Field Abnormality in both hemi-field and within 5° of fixation GRADING SYSTEM BY AAO
  • 18. AAO GUIDELINES: TARGET IOP Clinical conditions Target IOP 1. Mild glaucoma Reduction of 20% from baseline / IOP 17-18 mm of Hg 2. Moderate glaucoma Reduction of 30% from baseline/ IOP 14-16 mm of Hg 3. Advanced Glaucoma Reduction of 35-40% from baseline / IOP 10-12 mm of Hg 4. Ocular hypertension Reduction of 20% from baseline 6. Normal pressure glaucoma or NTG Reduction of 30% from baseline
  • 20. Recommended target IOPs in the Guidelines of the European Glaucoma Society (2003) POAG Target IOP Early Glaucoma <18 mm Hg Mod Glaucoma <15 mm Hg Adv Glaucoma <12 mm Hg Terminal Glaucoma <10 mm Hg NTG Target IOP Early Glaucoma <15 mm Hg Mod Glaucoma <12 mm Hg Adv Glaucoma <10 mm Hg
  • 21. HOW TO USE A TARGET PRESSURE  Draw an IOP curve for each glaucomatous patient and to highlight the target pressure on the curve.  Target pressures should be reevaluated periodically.  10 yrs later patient may develope any new systemic or ocular conditions that might affect the risk/benefit ratio of therapy.
  • 22. HOW TO USE A TARGET PRESSURE cont..  Target pressure needs to be lowered if glaucomatous damage is progressing despite IOP’s below the initially set target.  Conversely, the target IOP range may have to be increased if achieving the target IOP causes adverse ocular or systemic side effects.
  • 23. Listen to Expert “ You’re not going to have one target pressure that’s appropriate for every patient. It is a dynamic process and you always have to be alert and open to modification.” L. Jay Katz, Professor of Ophthalmology Jefferson Medical College
  • 24. Listen to Expert “Patients should be followed closely over time and their target pressures should be adjusted, depending upon how the patient is doing. If the patient progresses, the target pressure should be lowered. If the patient does very well, the target might be raised.” Stevens Simmons, Associate Clinical Professor, Albany Medical College
  • 26. Key Points  IOP is a significant, modifiable risk factor in Glaucoma  Lowering IOP to a target level is helpful across the spectrum of ds states & IOP levels:  Advanced glaucoma  Normal tension glaucoma  Newly diagnosed glaucoma  Target IOP range must be:  Individualized  Re-evaluated periodically